Quick Answer
BioNexus Gene Lab Corp reported Operating Income of -$1.57 million for fiscal year 2024.
BioNexus Gene Lab Corp Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$1.57M | +39.3% |
| 2023 | -$2.59M | -790.7% |
| 2022 | -$291.2K | -127.6% |
| 2021 | $1.06M | -17.1% |
| 2020 | $1.27M | +562.0% |
| 2019 | -$275.7K | -560.3% |
| 2018 | $59.9K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$702.5K | +47.5% | -14.9% |
| June 30, 2025 | -$611.3K | -335.9% | +1.2% |
| March 31, 2025 | -$618.4K | -682.5% | +53.8% |
| September 30, 2024 | -$1.34M | +47.1% | -616.1% |
| June 30, 2024 | $259.2K | +195.2% | +427.9% |
| March 31, 2024 | -$79.0K | -56.1% | +96.9% |
| September 30, 2023 | -$2.53M | -3777.2% | -828.9% |
| June 30, 2023 | -$272.2K | -97.3% | -437.6% |
- BioNexus Gene Lab Corp showed an increase of +39.3% in Operating Income compared to the prior fiscal year.
- Over the 2018–2024 period, BioNexus Gene Lab Corp’s operating income has declined by 2727.2% (from $59.9 thousand to -$1.57 million).
- The most recent figure is from BioNexus Gene Lab Corp’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: